Strategic priorities for respiratory syncytial virus (RSV) vaccine development

L J Anderson, P R Dormitzer, D J Nokes, R Rappuoli, A Roca, B S Graham, L J Anderson, P R Dormitzer, D J Nokes, R Rappuoli, A Roca, B S Graham

Abstract

Although RSV has been a high priority for vaccine development, efforts to develop a safe and effective vaccine have yet to lead to a licensed product. Clinical and epidemiologic features of RSV disease suggest there are at least 4 distinct target populations for vaccines, the RSV naïve young infant, the RSV naïve child ≥ 6 months of age, pregnant women (to provide passive protection to newborns), and the elderly. These target populations raise different safety and efficacy concerns and may require different vaccination strategies. The highest priority target population is the RSV naïve child. The occurrence of serious adverse events associated with the first vaccine candidate for young children, formalin inactivated RSV (FI-RSV), has focused vaccine development for the young RSV naïve child on live virus vaccines. Enhanced disease is not a concern for persons previously primed by a live virus infection. A variety of live-attenuated viruses have been developed with none yet achieving licensure. New live-attenuated RSV vaccines are being developed and evaluated that maybe sufficiently safe and efficacious to move to licensure. A variety of subunit vaccines are being developed and evaluated primarily for adults in whom enhanced disease is not a concern. An attenuated parainfluenza virus 3 vector expressing the RSV F protein was evaluated in RSV naïve children. Most of these candidate vaccines have used the RSV F protein in various vaccine platforms including virus-like particles, nanoparticles, formulated with adjuvants, and expressed by DNA or virus vectors. The other surface glycoprotein, the G protein, has also been used in candidate vaccines. We now have tools to make and evaluate a wide range of promising vaccines. Costly clinical trials in the target population are needed to evaluate and select candidate vaccines for advancement to efficacy trials. Better data on RSV-associated mortality in developing countries, better estimates of the risk of long term sequelae such as wheezing after infection, better measures of protection in target populations, and data on the costs and benefits of vaccines for target populations are needed to support and justify funding this process. Addressing these challenges and needs should improve the efficiency and speed of achieving a safe and effective, licensed RSV vaccine.

Copyright © 2013 Elsevier Ltd. All rights reserved.

References

    1. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588–598.
    1. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–1555.
    1. Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., Anderson L.J. Bronchiolitis-associated hospitalizations among U.S. children, 1980–1995. JAMA. 1999;282:1440–1447.
    1. Graham B.S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev. 2011;239:149–166.
    1. Hurwitz J.L. Respiratory syncytial virus vaccine development. Expert Rev Vaccines. 2011;10:1415–1433.
    1. van Bleek G.M., Osterhaus A.D., de Swart R.L. RSV 2010: recent advances in research on respiratory syncytial virus and other pneumoviruses. Vaccine. 2011;29:7285–7291.
    1. Chang J. Current progress on development of respiratory syncytial virus vaccine. BMB Reports. 2011;44:232–237.
    1. Collins P.L., Melero J.A. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 2011;162:80–99.
    1. Glezen W.P., Taber L.H., Frank A.L., Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140:543–546.
    1. Nokes D.J., Okiro E.A., Ngama M., Ochola R., White L.J., Scott P.D. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya. Clin Infect Dis. 2008;46:50–57.
    1. Cox M.J., Azevedo R.S., Cane P.A., Massad E., Medley G.F. Seroepidemiological study of respiratory syncytial virus in Sao Paulo state, Brazil. J Med Virol. 1998;55:234–239.
    1. Henderson F.W., Collier A.M., Clyde W.A., Jr., Denny F.W. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med. 1979;300:530–534.
    1. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749–1759.
    1. Sommer C., Resch B., Simoes E.A. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J. 2011;5:144–154.
    1. Stockman L.J., Curns A.T., Anderson L.J., Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997–2006. Pediatr Infect Dis J. 2012;31:5–9.
    1. Crowe J.E., Jr., Williams J.V. Immunology of viral respiratory tract infection in infancy. Paediatr Respir Rev. 2003;4:112–119.
    1. O’Callaghan-Gordo C., Bassat Q., Morais L., Diez-Padrisa N., Machevo S., Nhampossa T. Etiology and epidemiology of viral pneumonia among hospitalized children in rural Mozambique: a malaria endemic area with high prevalence of human immunodeficiency virus. Pediatr Infect Dis J. 2011;30:39–44.
    1. Robertson S.E., Roca A., Alonso P., Simoes E.A., Kartasasmita C.B., Olaleye D.O. Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. Bull World Health Organ. 2004;82:914–922.
    1. Madhi S.A., Schoub B., Simmank K., Blackburn N., Klugman K.P. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr. 2000;137:78–84.
    1. Chin J., Magoffin R.L., Shearer L.A., Schieble J.H., Lennette E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969;89:449–463.
    1. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., Meiklejohn G. Respiratory virus immunization: I. A field of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969;89:435–448.
    1. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89:405–421.
    1. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422–434.
    1. Wu P., Hartert T.V. Evidence for a causal relationship between respiratory syncytial virus infection and asthma. Expert Rev Anti Infect Ther. 2011;9:731–745.
    1. Groothuis J.R., Simoes E.A.F., Levin M.J., Hall C.B., Long C.E., Rodriguez W.J. Prophylactic administration of respiratory syncytial virus immune globulin in high-risk infants and young children. N Engl J Med. 1993;329:1524–1530.
    1. Glezen W.P., Paredes A., Allison J.E., Taber L.H., Frank A.L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981;98:708–715.
    1. Lamprecht C.L., Krause H.E., Mufson M.A. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis. 1981;134:211–217.
    1. Stensballe L.G., Ravn H., Kristensen K., Agerskov K., Meakins T., Aaby P. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol. 2009;123:398–403.
    1. Acedo L., Diez-Domingo J., Morano J.A., Villanueva R.J. Mathematical modelling of respiratory syncytial virus (RSV): vaccination strategies and budget applications. Epidemiol Infect. 2010;138:853–860.
    1. Belshe R.B., Newman F.K., Anderson E.L., Wright P.F., Karron R.A., Tollefson S. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis. 2004;190:2096–2103.
    1. Karron R.A., Wright P.F., Belshe R.B., Thumar B., Casey R., Newman F. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis. 2005;191:1093–1104.
    1. Luongo C., Yang L., Winter C.C., Spann K.M., Murphy B.R., Collins P.L. Codon stabilization analysis of the 248 temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates. Vaccine. 2009;27:5667–5676.
    1. Belshe R.B., Van Voris L.P., Mufson M.A. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis. 1982;145:311–319.
    1. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–537.
    1. Feltes T.F., Sondheimer H.M., Tulloh R.M., Harris B.S., Jensen K.M., Losonsky G.A. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011;70:186–191.
    1. Bernstein D.I., Malkin E., Abughali N., Falloon J., Yi T., Dubovsky F. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J. 2012;31:109–114.
    1. Waris M.E., Tsou C., Erdman D.D., Day D.B., Anderson L.J. Priming with live respiratory syncytial virus (RSV) prevents enhanced pulmonary inflammatory responses associated with formalin inactivated RSV immunization in BALB/c mice. J Virol. 1997;71:6935–6939.
    1. Falsey A.R., Walsh E.E., Capellan J., Gravenstein S., Zambon M., Yau E. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines—nonadjuvanted vaccine or vaccine adjuvanted with alum—given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis. 2008;198:1317–1326.
    1. Groothuis J., King S., Hogerman D., Paradiso P., Simoes E. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis. 1998;177:467–469.
    1. Anderson R., Huang Y., Langley J.M. Prospects for defined epitope vaccines for respiratory syncytial virus. Future Microbiol. 2010;5:585–602.
    1. Radu G.U., Caidi H., Miao C., Tripp R.A., Anderson L.J., Haynes L.M. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice. J Virol. 2010;84:9632–9636.
    1. Weber M.W., Milligan P., Hilton S., Lahai G., Whittle H., Mulholland E.K. Risk factors for severe respiratory syncytial virus infection leading to hospital admission in children in the Western Region of The Gambia. Int J Epidemiol. 1999;28:157–162.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever